Skip to main content
Premium Trial:

Request an Annual Quote

Ventana, Boehringer Ingelheim to Collaborate on CDx for Cancer Drugs

NEW YORK (GenomeWeb News) – Ventana Medical Systems and Boehringer Ingelheim announced today that they will collaborate on the development of companion diagnostic products for cancer drugs in the German drug firm's pipeline.

Ventana plans to utilize its immunohistochemistry technology platform and its experience in companion diagnostic development and premarket approval submissions to support Boehringer Ingelheim's personalized medicine strategies for cancer drug development, the firms said. The partners didn't name specific drug candidates or types of cancers that would be targeted by the collaboration.

Further terms of the alliance also were not disclosed.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.